Navigation Links
Fulgent Therapeutics Announces That CAP (College of American Pathologists) Has Accredited Their Clinical Laboratory
Date:10/24/2013

Temple City, CA (PRWEB) October 24, 2013

Fulgent Therapeutics, a CLIA Certified Laboratory, is proud to announce accreditation by the College of American Pathologists (CAP). CAP’s Laboratory Accreditation Program is recognized by the United States government as being equal-to or more-stringent-than the government’s own inspection program. With this accreditation, Fulgent's Diagnostic Lab is a part of an internationally recognized group of facilities that meet the highest standards of excellence and best practices in laboratory operations.    

The CAP accreditation process was comprised of CAP inspectors that examined Fulgent’s laboratory procedure, quality control, safety program, staff qualifications, equipment, facilities, and overall management and laboratory records.

Fulgent Therapeutics has recently announced a wide range of diagnostic panels for a variety of inherited diseases, including cardiology, pediatrics, and neurology as well as inherited cancer predisposition.

Additional information: info(at)fulgent-therapeutics(dot)com or 626-350-0537 x106.

About Fulgent Therapeutics LLC: Fulgent’s diagnostic lab was CLIA approved in May 2012. Fulgent Diagnostics provides affordable next generation genetic tests using massively parallel processes to a global community. Tests range from hereditary cancers to esoteric diseases. For a complete list of tests available please visit: fulgent-therapeutics.com/testing.    

About the College of American Pathologists:

The College of American Pathologists (CAP) is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the world’s largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care. More information about the CAP can be found at http://www.cap.org.

Fulgent Therapeutics LLC
4978 Santa Anita Ave, Ste. 205
Temple City, CA
91780

Read the full story at http://www.prweb.com/releases/2013/10/prweb11264218.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Fulgent Therapeutics Announces Their Comprehensive Hereditary Cancer Test Including BRCA1 and BRCA2 Analysis
2. Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at MarketPublishers.com
3. American Assoc. for Cancer Research co-hosts conference on molecular targets and cancer therapeutics
4. Global Dermatophytic Onychomycosis Therapeutics Market 2012 - 2016: Worldwide Industry Latest Market Share, Growth, Size, Trends, Strategy And Forecast Research Report
5. Global Huntington’s Disease Therapeutics Industry
6. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
7. Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
8. Multiple Sclerosis Therapeutics Market to 2019 – Treatment Diversification and Pipeline Innovation to Drive Growth, Says a New Report at RnRMarketResearch.com
9. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
10. Pain Management Therapeutics Market Will Decline USD 29.47 Billion in 2018 : Transparency Market Research
11. Pain Management Therapeutics Market Will Decline USD 29.47 Billion in 2018 : Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: